Men respond to dendritic-cell
vaccine --------------------------------------- Dendreon of Seattle said
that all 31 prostate-cancer patients in a phase-2 trial had an immune
response to Provenge, a dendritic-cell vaccine. Twenty of the men had a
strong response and six had a significant decrease in PSA level, reported
Dr. Eric Small of UC San Francisco in the Dec. 1 Journal of Clinical
Oncology. The vaccine contains an engineered antigen that is fused to a
patient’s own dendritic cells. According to the company, patients with
advanced hormone-refractory disease are being enrolled in phase-3
trials.
